The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.

Immunogenic or vaccine compositions for preventing malaria, comprising or encoding CSP N-terminal (NT) sequences capable of presenting NT epitopes to a subject, and methods of administering same.

The invention relates to a peptide structure which does not include a CH1 region, which recognises the SAG1 antigen of Toxoplasma gondii and which can neutralize the invasion of cells by Toxoplasma gondii, and to the use of said structure in the treatment of toxoplasmosis, in particular ocular toxoplasmosis, congenital toxoplasmosis and behavioural disorders linked to the presence of Toxoplasma gondii.

The invention relates to a peptide structure which does not include a CH1 region, which recognises the SAG1 antigen of Toxoplasma gondii and which can neutralize the invasion of cells by Toxoplasma gondii, and to the use of said structure in the treatment of toxoplasmosis, in particular ocular toxoplasmosis, congenital toxoplasmosis and behavioural disorders linked to the presence of Toxoplasma gondii.

Disclosed herein are compositions, kits, methods, and systems for detecting a target molecule in a sample using a detection molecule.

Disclosed herein are compositions, kits, methods, and systems for detecting a target molecule in a sample using a detection molecule.

The present invention describes methods of identifying high-risk populations or individuals who have positive serology for T.gondii. These methods include obtaining a biological sample from a subject; determining the level of T.gondii cyst antigen antibody in the biological sample; and characterizing the biological sample in at least one of three categories.

The present invention describes methods of identifying high-risk populations or individuals who have positive serology for T.gondii. These methods include obtaining a biological sample from a subject; determining the level of T.gondii cyst antigen antibody in the biological sample; and characterizing the biological sample in at least one of three categories.

The invention provides compositions and methods for preventing or reducing the severity of malaria.

The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I:
Q-YR.sup.1R.sup.2(I),
wherein Q, Y, R.sup.1, and R.sup.2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.